Paper Details

  1. Home
  2. Paper Details

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Author: Bazin-KarraD, BlancF, CacoubPatrice, CazorlaC, DecauxO, KarrasA, LambotteO, LonguetM, MussetL, PialouxG, PolS, Resche RigonM, SaadounDavid, ThibaultV, VittecoqD, ZizaJ M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Pegylated interferon α/ribavirin/protease inhibitor combination was highly effective in patients with hepatitis C virus-mixed cryoglobulinemia vasculitis. This combination should be administered cautiously considering the high rate of side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. OBJECTIVE: To analyse ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995244/

データ提供：米国国立医学図書館（NLM）

Combating Hepatitis C and Mixed Cryoglobulinemia: A New Approach

The world of [hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) vasculitis] is a challenging one, often riddled with complications. This study, much like a camel navigating a treacherous desert, explores the effectiveness of a novel treatment combination. Researchers investigated the efficacy and safety of [peg-IFNα/ribavirin/protease inhibitor] in patients with [HCV-MC vasculitis].

A Promising Oasis in a Challenging Landscape

The results show a significant virological response rate of [69.6%] at week 24. The combination therapy also led to a decrease in [cryoglobulin levels] and an increase in [C4 levels]. However, the study also highlights the potential for [adverse events], including [anemia, neutropenia, and thrombocytopenia].

Navigating the Challenges of HCV-MC Vasculitis

This study sheds light on a potential treatment strategy for [HCV-MC vasculitis]. While the combination therapy demonstrates promise, it's crucial to manage potential side effects. Healthcare professionals must carefully weigh the benefits and risks of this approach, considering each patient's individual needs and circumstances.

Dr. Camel's Conclusion

This study offers a hopeful glimpse into the treatment of HCV-MC vasculitis. The combination therapy shows promise in achieving virological response and improving clinical outcomes. However, it's crucial to be mindful of potential side effects and to work closely with a healthcare professional to tailor treatment plans to individual needs.

Date :
  1. Date Completed 2014-05-30
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

23606708

DOI: Digital Object Identifier

PMC3995244

Related Literature

Article Analysis
・Side Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.